Vical Shifts To Infectious Disease After Allovectin Fails In Melanoma
This article was originally published in The Pink Sheet Daily
CEO Vijay Samant defends Vical’s DNA-based technology platform after 20 years of development culminates in Phase III failure. But the platform still shows promise in other therapeutic areas, Vical says as the company absorbs a major blow to stock price.
You may also be interested in...
Company will focus on getting oral anti-fungal candidate VL-2397 over the finish line, after another pipeline blow-up.
Glaxo’s vaccine fails co-primary endpoint in Phase III DERMA study of melanoma – trial is allowed to continue but hopes for success are not high. Top-line release raises specter that drug could become yet another failed cancer vaccine.
Amgen explains why it has what it takes in immunotherapy, as part of a broader oncology development plan.